JOURNAL OF BUON, cilt.25, sa.3, ss.1625-1630, 2020 (SCI İndekslerine Giren Dergi)
Purpose: Enzalutamide and abiraterone acetate (AA) are the main therapeutic approaches for the treatment of metastatic castration-resistant prostate cancer (mCRPC) after the failure of androgen deprivation therapy during or following docetaxel-based chemotherapy. The aim of the present study was to investigate the role of early prostate-specific antigen (PSA) decline (four weeks after anti-androgen therapy) in predicting long-term progression free survival (PFS).